CLYM | tickerfilter.com

Fundamental analysis

28%

Profitability 0%

Dept financing 26%

Liquidity 50%

Performance 50%

Company vs Stock growth

N/A

+ Add row to compare

Performance

5 Days

-3.42%

1 Month

-19.86%

3 Months

-43.50%

6 Months

-78.10%

1 Year

-57.99%

2 Year

-59.64%

Key data

Stock price

$1.13

P/E Ratio

0.00

DAY RANGE

$1.10 - $1.28

EPS

-$1.53

52 WEEK RANGE

$1.05 - $11.55

52 WEEK CHANGE

-$57.68

MARKET CAP

121.003 M

YIELD

N/A

SHARES OUTSTANDING

0.000

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

05-14-2025

BETA

1.04

PUBLIC FLOAT

N/A

AVERAGE 10 VOLUME

$227,471

AVERAGE 30 VOLUME

$193,539

Company detail

CEO: Aoife M. Brennan
Region: US
Website: climbbio.com
Employees: 9
IPO year: 2021

Issue type:
Market: NASDAQ
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Climb Bio, Inc., a biotechnology company, focuses on developing therapies for autoimmune-driven inflammatory diseases. It develops budoprutug, an anti-CD19 monoclonal antibody for various autoimmune diseases, including systemic lupus erythematosus and lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wilmington, Delaware.

CLYM - Climb Bio, Inc.